EGFR and neoplasm: Likewise, osimertinib, with significant efficacy in treating NSCLC with the EGFR T790M mutation, shows less consistent outcomes in other tumor contexts, underscoring the need to address co-occurring alterations and heterogeneous tumor ecosystems [103].